Menu

Blog

Archive for the ‘bioengineering’ category

Jul 22, 2021

#TransVision Future Summit 2021 — Promo 1 (English)

Posted by in categories: bioengineering, biotech/medical, bitcoin, cryonics, geopolitics, lifeboat, nanotechnology, Ray Kurzweil, robotics/AI, singularity, space travel, transhumanism

Check out our new promo for #transvision #future Summit 2021! Get your tickets! -> www.TransVisionMadrid.com There will be talks about #longevity #artificialintelligence #cryonics and much much more. You will also be able to network with speakers and attendees during 5 optional dinner/cocktails, and 2 tours of several UNESCO heritage sites and historical places: Ávila, Segovia, Monsaterio de El Escorial, Valle de los Caídos (Valley of the Fallen), Aranjuez & Toledo.

Humanity Plus Humanity Plus Humanity Plus Magazine MUTISHAN Interactive Vivian Francos #SEOHashtag Alcor Life Extension Foundation Cryonics Institute Cryonics Institute SENS Research Foundation SENS Research Foundation Posthuman Network Posthuman Network Cryonics4U Longevity Conferences Longevity for All U.S. Transhumanist Party Transhumanist Party Australia Transhumanist Party Virtual Rational Transhumanism Singularity University Ray Kurzweil Singularity Singularity Hub Ray Kurzweil’s Singularity Singularity Network Transhumanismo Brasil Transhumanismo Brasil TRANSHUMANISMO Christian Transhumanist Association Mormon Transhumanist Association SingularityNET Singularitarianism Foresight Institute Lifeboat Foundation Lifeboat Foundation Machine Intelligence Research Institute KrioRus The Hedonistic Imperative — Paradise Engineering.

Continue reading “#TransVision Future Summit 2021 — Promo 1 (English)” »

Jul 22, 2021

Biological space race: NASA doctor reveals the future of genetically edited astronauts

Posted by in categories: bioengineering, biotech/medical, genetics

One of the scientists prodding and poking the Kelly brothers is Prof Christopher E Mason, the lead geneticist on the Twins Study. Mason’s lab at Cornell University is nothing if not ambitious. Its work centres on a “500-year plan for the survival of the human species on Earth, in space, and on other planets.”

As well as studying what happens to astronauts, it involves laying the genetic groundwork for humans to live among the stars. Mason envisions a future in which the human genome can be bioengineered to adapt to almost any environment, augmented with genes from other species that allow us to explore and settle the farthest corners of the Universe.

Jul 21, 2021

Scientists produce first genetically engineered marsupials

Posted by in categories: bioengineering, biotech/medical, genetics, life extension

We probably at this point should make all animals immortal: 3.


The advance promises to unlock new insights into human biology and disease, aiding in the study of everything from the developing immune system to tissue regeneration to skin cancer.

“Studying biodiversity is not just about exploring the biology of a bunch of interesting organisms, but ultimately for a better understanding of human biology,” developmental biologist and lead study author Hiroshi Kiyonari said via email.

Continue reading “Scientists produce first genetically engineered marsupials” »

Jul 21, 2021

Our Theory Of Aging & Blood Dilution w/ Saline & Albumin | Drs. Irina & Mike Conboy Interview Ep 1

Posted by in categories: bioengineering, biotech/medical, life extension, media & arts

In this video, Drs Irina and Mike Conboy talk about their theory of why we age and introduce Neutral Blood Exchange, which came from their original parabiosis experiments documented in a 2005 paper.

Our guests today are Drs. Irina and Michael Conboy of the Department of Bioengineering at the University of California Berkeley. their discovery of the rejuvenating effects of young blood through parabiosis in a seminal paper published in Nature in 2005 paved the way for a thriving field of rejuvenation biology. The Conboy lab currently focuses on broad rejuvenation of tissue maintenance and repair, stem cell niche engineering, elucidating the mechanisms underlying muscle stem cell aging, directed organogenesis, and making CRISPR a therapeutic reality.

Continue reading “Our Theory Of Aging & Blood Dilution w/ Saline & Albumin | Drs. Irina & Mike Conboy Interview Ep 1” »

Jul 20, 2021

Dr. Jean M. Hebert, Ph.D. — Replacing Aging — Albert Einstein College of Medicine

Posted by in categories: bioengineering, biotech/medical, genetics, life extension, neuroscience

Replacing Aging — Dr. Jean M. Hebert, Ph.D. Albert Einstein College of Medicine.


Dr. Jean M. Hebert, Ph.D. (https://einsteinmed.org/faculty/9069/jean-hebert/) is Professor in the Department of Genetics and in the Dominick P. Purpura Department of Neuroscience, at Albert Einstein College of Medicine.

Continue reading “Dr. Jean M. Hebert, Ph.D. — Replacing Aging — Albert Einstein College of Medicine” »

Jul 18, 2021

$315M Biotech Company Emerges From Stealth

Posted by in categories: bioengineering, biotech/medical, genetics

“Prime Editing is a wonderful example of the revolution in genetic medicine that we are living through,” said Robert Nelsen, co-founder and Managing Director of ARCH Venture Partners, one of several companies to fund Prime Medicine. “Gene editing technologies like this, when mature, could totally change our conception of what’s possible in treating disease.”

“This is an opportunity to take a giant step toward cures for a much wider range of diseases than previously possible,” said Stephen Knight, President and Managing Partner of F-Prime Capital, another backer of the new company.

The funds raised will be used to continue building the company, expand the capabilities of its technology platform and rapidly advance towards clinical indications. By the end of 2021, Prime Medicine expects to employ more than 100 people full-time.

Jul 17, 2021

Howard Leonhardt — Founder, Leonhardt Ventures — Bioelectrics & Biologics For Regeneration & Healing

Posted by in categories: bioengineering, biotech/medical, business, employment, neuroscience

Investing in the convergence of bioelectrics & biologics for regeneration & healing — howard J. leonhardt, founder, leonhardt ventures.


Howard Leonhardt is the Founder of Leonhardt Ventures, the world’s first Innovation Accelerator focused on the convergence of bioelectrics & biologics for organ regeneration and tissue healing.

Continue reading “Howard Leonhardt — Founder, Leonhardt Ventures — Bioelectrics & Biologics For Regeneration & Healing” »

Jul 15, 2021

Researchers Create New CRISPR Genetic Tools to Help Contain Mosquito Disease Transmission

Posted by in categories: bioengineering, biotech/medical, genetics

University of California San Diego scientists have now developed several genetic editing tools that help pave the way to an eventual gene drive designed to stop Culex mosquitoes from spreading disease. Gene drives are designed to spread modified genes, in this case those that disable the ability to transmit pathogens, throughout the targeted wild population.


Genetics toolkit targets less researched Culex mosquitoes, which transmit West Nile virus and avian malaria.

Continue reading “Researchers Create New CRISPR Genetic Tools to Help Contain Mosquito Disease Transmission” »

Jul 13, 2021

Exploring Synthetic Biology

Posted by in categories: bioengineering, biological

Here is a snapshot of our talks on synthetic biology. These videos will provide you with a basic understanding and appreciation for this field. These lectures start with an introduction to synthetic biology and go through the major discoveries and ethical controversies that arise from this field. You can check out the full Synthetic Biology Playlist here!

Jul 13, 2021

Gene research uncovers promising combination therapy for triple negative breast cancer

Posted by in categories: bioengineering, biotech/medical

Breast cancer is the leading cause of cancer death in women around the world, responsible for 1700 deaths every day. Although the vast majority of breast cancers are treatable, the most aggressive subtype—triple negative breast cancer (TNBC) – has a high recurrence rate, a high potential for metastasis and shows resistance to conventional treatments, leading to very poor prognosis and survival outcomes. A team of researchers at the Research Institute of the McGill University Health Center (RI-MUHC) conducted a preclinical study and discovered a novel targeted combination therapy that efficiently reduced tumor growth in metastatic breast cancer. Published in Nature Communications, their findings could lead to the development of a novel first line targeted therapy for the treatment of TNBC, with the prospect of rapidly transitioning to clinical trials in humans.

“There is no targeted therapy for TNBC. Chemotherapy treatment can even enrich these tumors in and be detrimental to the patient, as we have shown in a previous study,” says Dr. Jean-Jacques Lebrun, senior scientist in the Cancer Research Program at the RI-MUHC and principal investigator of the study. “Filling that huge medical gap was our motivation in conducting this study.”

While most breast cancers have one of three main receptors that are like entrance gates for treatments—estrogen, progesterone and a protein called human epidermal growth factor (HER2) – TNBC has none, thus the name triple negative . Using state-of-the-art technologies such as and genome-wide molecular approaches, the team identified two pathways which could be targeted in a therapeutic strategy.

Page 1 of 13412345678Last